Company intelligence / Profile preview

NeuroEM Therapeutics

Tampa, Florida, United Statesneuroem.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Early preclinical and human feasibility studies have shown that the TEMT-RF device can safely improve cognitive function in Alzheimer’s patients, with evidence of breaking up toxic beta amyloid and tau proteins. The company has completed a landmark human study demonstrating significant cognitive improvement, and pivotal trials are ongoing to support regulatory approval.

Therapeutic areas: Neurology
Modalities: Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

MemorEM

Phase 2

Indications: Alzheimer's disease

Partnerships

University of South Florida / USF Health Byrd Alzheimer’s InstituteLeft Coast EngineeringRF Exposure LabOcotillo ElectromagneticsRemarkable TechnologiesAxiom Clinical Research of FloridaInvicro/Konica MinoltaMegaNano Biotech Inc.

Beyond the preview

Go deeper on NeuroEM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroEM Therapeutics.

Explore the full profile